Clinical Trials Logo

Lung Cancer clinical trials

View clinical trials related to Lung Cancer.

Filter by:

NCT ID: NCT05431582 Not yet recruiting - Breast Cancer Clinical Trials

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Start date: December 30, 2022
Phase: Phase 1
Study type: Interventional

Primary Objectives are to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of ZN-c3 and ZN-c3 and bevacizumab or ZN-c3 and bevacizumab plus pembrolizumab in metastatic CCNE1 amplified and TP53 mutant solid tumors as well to evaluate antitumor activity of ZN-c3 and bevacizumab or ZN-c3 and bevacizumab plus pembrolizumab in metastatic CCNE1 amplified and TP53 mutant solid tumors.

NCT ID: NCT05427214 Not yet recruiting - Lung Cancer Clinical Trials

Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy

Dragon
Start date: August 31, 2022
Phase: N/A
Study type: Interventional

This prospective imaging study is evaluating the feasibility of using the Halcyon 4.0 radiotherapy system for radiation therapy planning in patients with cancer. The Halcyon 4.0 system has been engineered to decrease the image acquisition time and the radiation exposure, but the system has not yet been clinically validated for use in radiation planning. This pilot study will evaluate images obtained on the Halcyon 4.0 system to assess if the quality is sufficient for radiation treatment plan construction.

NCT ID: NCT05426135 Recruiting - Lung Cancer Clinical Trials

Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment

Start date: June 1, 2022
Phase:
Study type: Observational

To improve the accuracy of risk prediction, screening and treatment outcome of cancer, we aim to establish a medical database that includes standardized and structured clinical diagnosis and treatment information, image features, pathological features, and multi-omics information and to develop a multi-modal data fusion-based technology system using artificial intelligence technology based on database.

NCT ID: NCT05423236 Not yet recruiting - Lung Cancer Clinical Trials

Clinical Characteristics of Lung Cancer in China

Start date: July 1, 2022
Phase:
Study type: Observational

This study is a single-center, real-world and large-population-based retrospective study. In the current study, the investigators not only describe the changes of demographic and basic clinicopathological characteristics of lung cancer during recent years but delineate the correlation between clinicopathological features and common clinical blood tests in such a large population.

NCT ID: NCT05419076 Recruiting - Lung Cancer Clinical Trials

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

Start date: June 10, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

NCT ID: NCT05417672 Recruiting - Lung Cancer Clinical Trials

Assessment of Relationship Between Preoperative Nutritional Status and Perioperative/Postoperative Conditions in Patients With Lung Cancer Scheduled for Lobectomy

Start date: September 29, 2021
Phase:
Study type: Observational

Malnutrition is common in patients with lung cancer. In patients with malnutrition risk, the risk of complications is high both in the perioperative, early and late postoperative periods. Malnutrition is an independent risk factor for length of hospital stay and cost in these patients. Patients with lung cancer may have many morbidities in postoperative period, especially problems with wound healing. Therefore, assessment of the nutritional status of patients with lung cancer should begin at the diagnosis stage.

NCT ID: NCT05403177 Recruiting - Breast Cancer Clinical Trials

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

Start date: June 13, 2022
Phase:
Study type: Observational

The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

NCT ID: NCT05401110 Not yet recruiting - Lung Cancer Clinical Trials

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Start date: August 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objective response rate, duration of response, progression-free survival, and disease control rate, along with assessing biomarkers through tumor tissue and circulating tumor DNA.

NCT ID: NCT05400226 Recruiting - Lung Cancer Clinical Trials

Phase 2 Study of VGT-309 in Lung Cancer

Start date: May 24, 2022
Phase: Phase 2
Study type: Interventional

A Phase 2 open label study to evaluate safety and efficacy of VGT-309 to identify cancer in up to 40 subjects undergoing lung cancer surgery.

NCT ID: NCT05400070 Recruiting - Lung Cancer Clinical Trials

Neoadjuvant PD-1 Inhibitor, Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Start date: May 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

primary purposeļ¼šObserve the pathological complete response rate (PCR) of postoperative tumor tissue resection and evaluate the safety of the treatment process.